REGISTERED NUMBER: 09563670 (England and Wales)

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

SOLENO THERAPEUTICS UK LTD

Page

Company information

1

Balance sheet

2

Notes to the financial statements

3

Directors:

Mr M C Abernethy

Mr D L Bradfute

Mr D M Lippoldt

Registered office:

Suite 4, 7th Floor

50 Broadway

London

SW1H 0DB

Registered number:

09563670 (England and Wales)

Auditors:

Nortons Assurance Limited

Chartered Accountants & Statutory Auditor

Second Floor

NOW Building

Thames Valley Park

Reading

Berkshire

RG6 1RB

CURRENT ASSETS

Debtors

4

759,883

1,144,401

Cash at bank

11,577

193,173

771,460

1,337,574

CREDITORS

Amounts falling due within one year

5

(293,708

)

(1,013,756

)

NET CURRENT ASSETS

477,752

323,818

TOTAL ASSETS LESS CURRENT LIABILITIES

477,752

323,818

CAPITAL AND RESERVES

Called up share capital

152

152

Retained earnings

477,600

323,666

477,752

323,818

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 October 2026 and were signed on its behalf by:

Mr M C Abernethy - Director

1.	STATUTORY INFORMATION

Soleno Therapeutics UK Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The company's functional and presentational currency is US Dollar ($) and the financial statements have been rounded to the nearest Dollar ($).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover

Turnover represents income earned from the parent company calculated on a cost plus basis, excluding Value Added Tax.

Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into.

Basic financial liabilities

Basic financial liabilities, including creditors, and loans from fellow group companies are initially recognised at transaction price.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are initially recognised at transaction price.

Taxation

Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Assets and liabilities in foreign currencies are translated into dollars (USD) at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into dollars (USD) at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Going concern

The company is reliant on the ongoing support of its parent company to meet its day to day liabilities. The directors have received confirmation of continued financial support for the foreseeable future from its ultimate parent company, Neurocrine Biosciences, Inc., thus the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and continue to adopt the going concern basis of accounting in preparing the annual financial statements.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2024 - NIL).

4.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31/12/25

31/12/24

(Unaudited)

$

$

Amounts owed by group undertakings

695,739

1,137,983

Other debtors

64,144

6,418

759,883

1,144,401

5.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31/12/25

31/12/24

(Unaudited)

$

$

Trade creditors

65,964

77,623

Tax

51,310

943

Accruals

176,434

935,190

293,708

1,013,756

6.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the auditors was unqualified.

Karen Cairns (Senior Statutory Auditor)

for and on behalf of Nortons Assurance Limited

7.	RELATED PARTY DISCLOSURES

At the balance sheet date, the company's immediate and ultimate parent company was Soleno Therapeutics Inc, a company registered in the United States of America. Their registered office is located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065, United States of America.

The parent of the smallest group for which consolidated financial statements are drawn up of which the company is a member is Soleno Therapeutics Inc.

8.	POST BALANCE SHEET EVENTS

On 18 May 2026, the company's parent Soleno Therapeutics Inc, was acquired by Neurocrine Biosciences, Inc. At that date, Neurocrine Biosciences, Inc became the company's ultimate parent.